IgE binding epitope

IgE binding epitopes are specific short regions (linear or conformational) on allergenic proteins recognized by IgE antibodies. When an individual is sensitized, their IgE binds to these epitopes on the allergen, leading to mast cell or basophil activation and allergic symptoms. These epitopes are essential in defining allergenicity and determining cross-reactivity among related allergens. Mapping and modifying such epitopes has enabled better prediction of cross-reactivity, development of hypoallergenic therapeutics, and identification of biomarkers for allergy diagnosis and prognosis[1][3][5][6]. Key contextual notes: - "IgE binding epitope" describes sites on proteins (allergens) that bind IgE, not a unique protein, receptor, or drug target[1][3][5][6]. - Therapeutically, most allergy treatments target IgE itself (e.g., omalizumab) or use allergen variants engineered to reduce IgE binding[3]. - In allergy research, specific IgE reactivity to certain epitope sequences is used as a biomarker (e.g., persistence of egg allergy is linked to IgE reactivity against sequential ovomucoid epitopes)[5].

Other names

IgE epitopeIgE-binding siteIgE-reactive region